2. Disease Areas
  3. Blood or Cardio-cerebrovascular Disease
  4. Heart Disease
  5. Atrial Fibrillation

Atrial Fibrillation

Atrial fibrillation (AFib) is a common and serious cardiac arrhythmia characterized by rapid, irregular electrical activity in the atria, leading to ineffective atrial contractions and an irregularly irregular ventricular response. It results from disorganized atrial impulses, often exceeding 500 per minute, which overwhelm the AV node and cause chaotic ventricular activation. This condition is associated with abnormal automaticity and reentry mechanisms, and it significantly increases the risk of stroke due to blood stasis and clot formation in the left atrial appendage. AFib can present as paroxysmal, persistent, or permanent, with symptoms including palpitations, fatigue, shortness of breath, dizziness, and chest discomfort. Risk factors include advancing age, hypertension, obesity, diabetes, heart failure, and structural heart disease. If untreated, it can lead to reduced cardiac output, heart failure, and long-term complications, necessitating prompt medical evaluation and management to prevent morbidity and mortality.

Atrial Fibrillation (2):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-103175
    PSB36 524944-72-7 99.94%
    PSB36 is a highly selective A1 adenosine receptor antagonist, with a Ki of 0.12 nM and a Kd of 0.7 nM. Systemic administration of PSB36 reduces formalin- and Carrageenan (HY-125474)-induced edema in mice and decreases pain-related behaviors, with no local paw activity. PSB36 prolongs the APD90 of rat and human atria, produces a frequency-dependent prolongation of rat atrial ERP, increases the diastolic threshold of rat atria, and shortens the duration of atrial fibrillation episodes. PSB36 can be used in research related to inflammatory pain, inflammatory hyperalgesia, edema and atrial fibrillation.
    PSB36
  • HY-119124
    Edoxaban M4 834919-19-6 98.83%
    Edoxaban M4 (D21-2393) is an orally active and selective Factor Xa inhibitor with a human Factor Xa IC50 of 1.8 nM. Edoxaban M4 exhibits anticoagulant activity via Factor Xa inhibition. Edoxaban M4 can be used for the research of non-valvular atrial fibrillation, venous thromboembolisms, pulmonary embolism.
    Edoxaban M4